title: New Approaches in Immunotherapy for the Treatment of Lung Cancer.
abstract: Despite the several advances in the last few years into treatment of advanced lung cancer, the 5-year survival remains extremely low. New therapeutic strategies are currently under investigation, and immunotherapy seems to offer a promising treatment alternative. In the last decade, therapeutic cancer vaccines in lung cancer have been rather disappointing, mainly due to the lack of efficient predictive biomarkers. A better refinement of the patient population that might respond to treatment might finally lead to a success story. For the first time, the immune checkpoint inhibitors are demonstrating sustained antitumor response and improved survival and they may be the first immunotherapeutics available for patients with lung cancer.
authors.affiliation: Kymab Ltd, The Bennet Building (B930), Babraham Research Campus, Cambridge, CB22 3AT, UK. sonia.quaratino@novartis.com.
authors.forename: Sonia
authors.initials: S
authors.lastname: Quaratino
authors.affiliation: Bayer Pharma AG, Müllerstraße 178, 13353, Berlin, Germany.
authors.forename: Ulf
authors.initials: U
authors.lastname: Forssmann
authors.affiliation: Affimed Therapeutics AG, Technologiepark, Im Neuenheimer Feld 528, 69120, Heidelberg, Germany.
authors.forename: Jens-Peter
authors.initials: JP
authors.lastname: Marschner
mesh_terms: D006801:Humans; D007167:Immunotherapy; D008175:Lung Neoplasms / Q000276:immunology* / Q000628:therapy*